Severe post-kala-azar dermal leishmaniasis successfully treated with miltefosine in an Ethiopian HIV patient

Charles Abongomera, Tullia Battaglioli, Cherinet Adera, Koert Ritmeijer

    Research output: Contribution to journalA1: Web of Science-article

    1 Downloads (Pure)

    Abstract

    Post-kala-azar dermal leishmaniasis (PKDL) is a neglected tropical disease characterized by a dermatosis which often appears after successful treatment of visceral leishmaniasis caused by Leishmania donovani. PKDL treatment options are few and have severe limitations. In East-Africa, the standard treatment of PKDL is with daily painful potentially toxic sodium stibogluconate injections, administered for a prolonged duration of 30-60 days. In the Indian subcontinent, PKDL is mainly treated with miltefosine, a safer orally administered drug. However, in East-Africa, there is very limited experience in the use of miltefosine for treatment of severe PKDL, with only one published case report. Here we report a severe PKDL case in an Ethiopian HIV patient successfully treated with oral miltefosine (100mg/day for 28 days). Miltefosine was efficacious, safe and well tolerated, suggesting that it can play an important role in the treatment of severe PKDL also in East-African patients. Further research is warranted.

    Original languageEnglish
    JournalInternational Journal of Infectious Diseases
    Volume81
    Pages (from-to)221-224
    Number of pages4
    ISSN1201-9712
    DOIs
    Publication statusPublished - 2019

    Keywords

    • Administration, Oral
    • Adult
    • Antiprotozoal Agents/administration & dosage
    • Ethiopia
    • HIV Infections/complications
    • Humans
    • Leishmania donovani/drug effects
    • Leishmaniasis, Cutaneous/drug therapy
    • Male
    • Phosphorylcholine/administration & dosage

    Fingerprint

    Dive into the research topics of 'Severe post-kala-azar dermal leishmaniasis successfully treated with miltefosine in an Ethiopian HIV patient'. Together they form a unique fingerprint.

    Cite this